Daiichi Looks To Carve U.S. Anticoagulant Niche With Savaysa
This article was originally published in PharmAsia News
Executive Summary
As a late entrant to the novel oral anticoagulant market, the Japanese pharma faces stiff competition from other players, but could still carve out a part of the warfarin market.